# Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/TPST/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: TPST
Company: Tempest Therapeutics
Source: Tempest Therapeutics
Published: 2026-05-14 20:15 EST
Original Source URL: https://ir.tempesttx.com
## Summary

Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of

## Article Body
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Manufacturing Partner Appointed Andrew Fang, Ph.D., as Head of
## Recent Company News
- 2026-05-29 12:00 EST — [Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds](https://biopharmsignal.com/news/TPST/tempest-therapeutics-announces-warrant-exercise-for-approximately-2-million-in-gross-proceeds) — Source: Tempest Therapeutics
- 2026-05-14 20:15 EST — [Tempest Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/TPST/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Tempest Therapeutics
- 2026-05-06 11:00 EST — [Tempest Presents Clinical Update at ISCT 2026 Annual Meeting](https://biopharmsignal.com/news/TPST/tempest-presents-clinical-update-at-isct-2026-annual-meeting) — Source: Tempest Therapeutics
- 2026-04-29 12:00 EST — [Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting](https://biopharmsignal.com/news/TPST/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting) — Source: Tempest Therapeutics
- 2026-04-22 12:00 EST — [Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T](https://biopharmsignal.com/news/TPST/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19-bcma-car-t) — Source: Tempest Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)